Fig. 4
From: Genome-wide CRISPR screen identifies ESPL1 limits the response of gastric cancer cells to apatinib
These candidate genes are valuable biomarkers in clinical GC samples. a The MCM2, CCND3, ESPL1, PLK1, TCF7 and VANGL1 mRNA expression was selectively up-regulated in GC from TCGA database; b ESPL1 protein showed positive, moderate or weak immunostaining in cell cytoplasmic of GC tissues from a tissue microarray; c ESPL1 protein level was significantly elevated in GC patients with pathological grade III (IRS, 5.48 ± 2.55, N = 25) compared with that in patients of pathological grade II (IRS, 3.88 ± 2.22, N = 16). Statistical significance was determined by t-test. Data were represented as means ± SD. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001 compared with the NC group